These findings collectively suggest that RB1 mutation mediates sensitivity to PARPis such as Olaparib, Rucaparib, and Niraparib through its crucial role in facilitating DNA DSB repair via HR and in modulating immune responses within the tumor microenvironment. Here, RB1 is linked to neoplasm.